|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Acquired in-process research and development | |||||
| Research and development | |||||
| General and administrative | |||||
| Loss on impairment of goodwill | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Change in fair value of warrant liability | |||||
| Interest income and other, net | |||||
| Net loss | |||||
| Loss attributable to common stockholders | |||||
| Net loss per share attributable to common stockholders - basic | |||||
| Net loss per share attributable to common stockholders - diluted | |||||
| Total net loss per share - basic | |||||
| Total net loss per share - diluted | |||||
| Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic | |||||
| Weighted-average number of common shares used in net loss per share attributable to common stockholders - diluted | |||||
Loading...